Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL729746 | 0.84 | MEN1 (0.37) | — | |
| SCHEMBL7260793 | 0.75 | KCNH2 (0.34) | — | |
| SCHEMBL732273 | 0.74 | GSK3B (0.35) | — | |
| SCHEMBL730013 | 0.73 | ALDH1A1 (0.32) | — | |
| SCHEMBL7081435 | 0.70 | KMT2A (0.37) | — | |
| SCHEMBL28104746 | 0.70 | — | — | |
| SCHEMBL6772665 | 0.68 | — | — | |
| SCHEMBL5798680 | 0.66 | KCNN4 (0.40) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL731885 | 0.66 | AGER (0.35) | — | |
| SCHEMBL28813721 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138176-B2 | Imidazo compounds | NOVARTIS AG (CH) | 2012-03-20 | — | — | US | disclosed |
| US-20110092492-A1 | IMIDAZO COMPOUNDS | HEROLD PETER | 2011-04-21 | — | — | US | disclosed |
| US-7879847-B2 | such as 4-(5,6-Dihydro-8H-imidazo[5,1-c][1,4]oxazin-5-yl)benzonitrile, having aldosterone synthase and/or 11- beta -hydroxylase inhibitory activity, used for the treatment of hypertension and Cushing's Syndrome | NOVARTIS AG (CH) | 2011-02-01 | — | — | US | disclosed |
| EP-2007770-B1 | IMIDAZO COMPOUNDS | NOVARTIS AG (CH) | 2010-09-08 | — | — | EP | disclosed |
| EP-2007771-B1 | IMIDAZO COMPOUNDS | NOVARTIS AG (CH) | 2010-04-07 | — | — | EP | disclosed |
| US-20090192149-A1 | Imidazo Compounds | SPEEDEL EXPERIMENTA AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20090192144-A1 | Imidazo Compounds | SPEEDEL EXPERIMENTA AG (CH) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192149-A1 | Imidazo Compounds | CYP19A1, CYP11B2, GPER1 | SLC6A2 3668/4885SLC6A4 3642/4885SLC6A3 3857/4885 |
| US-20090192144-A1 | Imidazo Compounds | REN, CYP11B2, CYP11B1 | SLC6A2 1624/4885SLC6A4 2232/4885SLC6A3 2424/4885 |
| US-20110092492-A1 | IMIDAZO COMPOUNDS | REN, CYP11B2, CYP11B1 | SLC6A2 1673/4885SLC6A4 2087/4885SLC6A3 2321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.